Catalog No.
Product Name
Application
Product Information
Citations
-
NLRP3 Inflammasome Inhibitor
NLRP3-IN-17 is a selective and orally bioactive inhibitor of the NLRP3 inflammasome, exhibiting an IC50 value of 7 nM. This compound effectively inhibits NLRP3-dependent secretion of IL-1β in murine models, making it a valuable tool for investigating the mechanisms underlying chronic inflammatory diseases. NLRP3-IN-17 is suited for research applications focused on the modulation of immune responses and the development of therapeutic strategies targeting inflammatory pathways. -
P2Y14R Antagonist
P2Y14R Antagonist 1 is a highly selective antagonist of the P2Y14 receptor, exhibiting an IC50 of 0.6 nM. It demonstrates significant antagonistic activity against P2Y14R, with both in vitro and in vivo efficacy, along with favorable pharmacokinetic properties. This compound effectively reduces the release of inflammatory mediators and mitigates cell pyroptosis through the NLRP3/Gasdermin D signaling pathway. P2Y14R Antagonist 1 is a valuable tool for research investigating acute gouty arthritis and related inflammatory conditions. -
NLRP3 Inhibitor
NLRP3-IN-21 is a selective NLRP3 inflammasome inhibitor that effectively mitigates inflammatory processes. This compound disrupts NLRP3 inflammasome activation and inhibits pyroptosis by preventing gasdermin D cleavage, ASC oligomerization, and the assembly of the inflammasome complex. NLRP3-IN-21 is valuable for research applications focused on understanding inflammatory diseases and developing potential therapeutic strategies targeting the NLRP3 pathway. -
NLRP3 Inhibitor
JT001 sodium is a selective and orally bioavailable inhibitor of the NLRP3 inflammasome. By disrupting NLRP3 assembly, it effectively inhibits the release of pro-inflammatory cytokines and prevents pyroptosis. This compound is valuable for research into nonalcoholic steatohepatitis and liver fibrosis, providing insights into potential therapeutic strategies for these conditions. -
NLRP3 Inhibitor
NLRP3-IN-80 is a selective inhibitor of the NLRP3 inflammasome, a key component in the regulation of inflammatory responses. This compound demonstrates potent inhibitory activity, making it valuable for studying the mechanisms of inflammaging and related inflammatory diseases. NLRP3-IN-80 is suitable for both in vitro and in vivo research applications aimed at understanding chronic inflammation and its implications in various pathologies. -
NLRP3 Inhibitor
NLRP3-IN-2 is a selective inhibitor of the NLRP3 inflammasome, effectively suppressing its formation in cardiomyocytes. This compound demonstrates the ability to reduce infarct size following myocardial ischemia/reperfusion injury in mouse models, while leaving glucose metabolism unaffected. NLRP3-IN-2 is useful in research focused on inflammasome-related pathways and may offer insights into therapeutic strategies for cardiac conditions. -
NLRP3 Inhibitor
AMS-17 is a potent inhibitor of the NLRP3 inflammasome, effectively suppressing microglial activation both in vitro and in vivo. It demonstrates the ability to inhibit the production of key pro-inflammatory cytokines, including caspase-1, TNF-α, IL-1β, and inducible nitric oxide synthase (iNOS) in N9 cells. This compound is valuable for research focused on inflammation-associated neurological disorders, such as vascular dementia (VaD). -
NLRP3 Inhibitor
NLRP3-IN-25 is an orally available NLRP3 inhibitor that exhibits significant anti-inflammatory properties. It effectively reduces renal injury in a doxorubicin-induced glomerulonephritis model in mice. Additionally, NLRP3-IN-25 demonstrates the ability to inhibit IL-1β secretion in THP-1 cells, with an IC50 value of 21 nM, making it a valuable tool for research into NLRP3-related inflammatory conditions. -
Stable Isotope
(±)11(12)-EET-d11 is a deuterium-labeled analog of (±)11(12)-EET, which acts as an inhibitor of the NLRP3 inflammasome. This compound is important for studies investigating anti-inflammatory pathways, angiogenesis, and cardioprotection. The stable isotope labeling allows for enhanced tracking and analysis in various biological assays and helps elucidate the role of (±)11(12)-EET in cellular and molecular processes. -
NLRP3 Inhibitor
Emlenoflast sodium is a potent and selective inhibitor of the NLRP3 inflammasome, exhibiting an IC50 of less than 100 nM. This sulfonylurea compound plays a significant role in studies related to inflammatory diseases, enabling researchers to explore the mechanistic pathways and therapeutic potentials linked to NLRP3 modulation. Its specificity and efficacy make it a valuable tool for investigating the underlying mechanisms of inflammation and related disorders. -
PC Inhibitor
Anemoside A3-methyl 6-aminohexanoate is a potent pyruvate carboxylase (PC) inhibitor, exhibiting a Kd value of 10.1 μM against human PC. This compound influences cellular pathways through the PC/NF-κB/NLRP3 inflammasome axis, demonstrating significant efficacy in alleviating symptoms of DSS-induced colitis in murine models. Anemoside A3-methyl 6-aminohexanoate serves as a useful tool in colitis-related research and studies focusing on the modulation of inflammatory pathways. -
NLRP3 Inhibitor
NLRP3-IN-79 is a potent, orally active inhibitor of the NLRP3 inflammasome, with an IC50 of 10.69 nM. It functions by directly binding to NLRP3, disrupting the NEK7-NLRP3 interaction and preventing inflammasome assembly. This compound is valuable for research into NLRP3-related diseases, such as systemic inflammation, peritonitis, and colitis, facilitating insights into therapeutic strategies targeting inflammasome-mediated pathways. -
NLRP3 Inflammasome Inhibitor
D359-0396 is an orally active inhibitor of the NLRP3 inflammasome. This compound effectively inhibits pyroptosis and the release of IL-1β in macrophages by preventing the oligomerization of NLRP3 and ASC, as well as the cleavage of GSDMD. D359-0396 has demonstrated therapeutic potential in experimental autoimmune encephalomyelitis (EAE) and enhances survival rates in murine models of septic shock. This reagent is suitable for research applications focused on inflammation and immune response modulation. -
NLRP3 Inhibitor
JC-171 is a selective NLRP3 inflammasome inhibitor that demonstrates an IC50 of 8.45 μM in blocking LPS/ATP-induced interleukin-1β (IL-1β) release from J774A.1 macrophages. This compound is valuable for research focused on the roles of NLRP3 in inflammatory diseases, as it allows for the investigation of inflammasome activation and associated cytokine release pathways. Its specificity makes it a useful tool in studying the modulation of innate immune responses in various experimental models. -
NLRP3 Inhibitor
JT001 is a potent and selective orally active inhibitor of NLRP3, targeting the NLRP3 inflammasome. By inhibiting the assembly of the inflammasome, JT001 effectively reduces cytokine release and prevents pyroptosis, allowing for potential therapeutic implications. This compound is valuable for research applications focusing on nonalcoholic steatohepatitis and liver fibrosis. -
NLRP3 Inhibitor
NLRP3-IN-18 is a selective inhibitor of the NLRP3 inflammasome, demonstrating potent activity with an IC50 value of ≤1.0 µM. This compound is instrumental in research focused on inflammation, providing insights into NLRP3-related pathways and their role in various diseases. NLRP3-IN-18 is suitable for studies investigating the modulation of inflammatory responses and the development of therapeutic strategies targeting NLRP3. -
NLRP3 Proteins Inhibitor
NLRP3-IN-11 is a potent inhibitor of NLR family pyrin domain containing 3 (NLRP3) proteins, exhibiting an IC50 value of less than 0.3 μM. It demonstrates significant biological activity in modulating NLRP3 signaling, making it a valuable tool for research into inflammatory and degenerative diseases. Applications include the study of non-alcoholic steatohepatitis (NASH), atherosclerosis, Alzheimer's disease, Parkinson's disease, diabetes, gout, and various autoinflammatory conditions. -
NLRP3 Inhibitor
INF4E is a potent inhibitor of the NLRP3 inflammasome, effectively targeting both caspase-1 and NLRP3 ATPase activities. This compound demonstrates significant protective effects against ischemia-reperfusion-induced myocardial injury and dysfunction. INF4E is valuable for research applications focused on inflammatory diseases and cardioprotection mechanisms. -
NLRP3 Inhibitor
NT-0249 is a selective inhibitor of the NLRP3 inflammasome, targeting key inflammatory pathways. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research into diseases associated with inflammasome dysregulation. NT-0249 can be utilized in studies exploring the roles of NLRP3 in conditions such as autoimmune disorders and metabolic syndromes. -
NLRP3 Inflammasome Inhibitor
NLRP3-IN-NBC6 is a selective inhibitor of the NLRP3 inflammasome, exhibiting an IC50 of 574 nM and functioning independently of calcium ions. It effectively inhibits Nigericin-induced inflammasome activation in THP-1 cells and reduces IL-1β release in response to Imiquimod from LPS-primed bone marrow-derived macrophages. This compound is valuable for studying the role of inflammasome activation in various inflammatory diseases and metabolic disorders. -
NLRP3/Pyroptosis Inhibitor
Antcin A is a potent inhibitor of the NLRP3 inflammasome, effectively disrupting its assembly and activation. This compound demonstrates significant biological activity by inhibiting pyroptosis in Kupffer cells, thereby offering liver protective properties. Antcin A is valuable for research focused on inflammation and can be particularly useful in studies related to non-alcoholic fatty liver disease. -
NLRP3 inflammasome Inhibitor
NBC19 is an inhibitor of the NLRP3 inflammasome, exhibiting an IC50 of 60 nM in differentiated THP1 cells. This compound effectively inhibits IL-1β release triggered by nigericin and ATP, with IC50 values of 80 nM and 850 nM, respectively. NBC19 serves as a valuable tool for investigating the role of the NLRP3 inflammasome in inflammatory processes and related research applications. -
NLRP3 Inhibitor
Selnoflast calcium is a selective and reversible small molecule inhibitor targeting the NLRP3 inflammasome. It effectively suppresses the release of IL-1β in response to NLRP3 activation, particularly in human monocyte-derived macrophages associated with Alzheimer's disease. This compound holds potential for advancing research in Alzheimer's as well as other systemic inflammatory diseases, including ulcerative colitis and chronic obstructive pulmonary disease. -
Anti-inflammatory Agent
NLRP3-IN-72 is a benzimidazole derivative that functions as an anti-inflammatory agent by specifically targeting the NLRP3 inflammasome. It demonstrates significant biological activity with an IC50 of 0.3 μM for inhibiting NLRP3-mediated IL-1β secretion, a PD50 of 0.4 μM for protecting against pyroptosis, and an EC50 of 0.6 μM for the induction of heme oxygenase-1 (HO-1). These properties make NLRP3-IN-72 a valuable tool for research into inflammatory processes and potential therapeutic interventions. -
NLRP3 Inhibitor
NLRP3-IN-44 is a selective inhibitor of the NLRP3 inflammasome, exhibiting potent activity with a Kd of 17.5 nM and approximately 62% oral bioavailability. This compound facilitates research into NLRP3-related pathologies by effectively modulating inflammasome activity. NLRP3-IN-44 is valuable for investigations into the roles of the NLRP3 inflammasome in inflammatory diseases. -
NLRP3 Inhibitor
NLRP3-IN-70 is an inhibitor of the NLRP3 inflammasome, specifically designed to bind to the NACHT domain of the NLRP3 protein. By blocking the interaction between NLRP3 and ASC, it disrupts ASC oligomerization and subsequent inflammasome assembly. This compound is valuable for research into conditions such as sepsis and nonalcoholic steatohepatitis, providing insights into the regulation of inflammatory responses. -
NLRP3 Inhibitor
NLRP3-IN-29 is a selective inhibitor of the NLR family pyrin domain-containing protein 3 (NLRP3). It demonstrates significant potential for blood-brain barrier permeability and efficacy in inhibiting inflammation both in vitro and in vivo. NLRP3-IN-29 is particularly valuable for research related to Alzheimer's disease and other neuroinflammatory conditions. -
NLRP3 Inhibitor
Yadanzigan is a potent NLRP3 inhibitor that exerts its anti-inflammatory effects by inhibiting the NF-κB signaling pathway and reducing Reactive Oxygen Species production. This compound has been shown to mitigate LPS-induced acute lung injury (ALI) in murine models, highlighting its potential for research in inflammation-related conditions. Its mechanism of action positions Yadanzigan as a valuable tool for studying NLRP3-related pathways and their roles in various pathological processes. -
NLRP3 Inhibitor
NLRP3-IN-9 is a potent inhibitor of the NLRP3 inflammasome, targeting its activation pathway. This compound effectively inhibits the release of interleukin-1 beta (IL-1β), thereby reducing inflammation and mechanical hyperalgesia. NLRP3-IN-9 has significant potential for research applications related to gout and other inflammatory disorders. -
NLRP3 Inhibitor
NLRP3-IN-43 is a potent inhibitor of NLRP3 inflammasome activation, specifically targeting the leucine-rich repeat (LRR) domain. By disrupting the interaction between NLRP3 and NEK7, this compound effectively inhibits the downstream signaling pathways associated with inflammatory responses. NLRP3-IN-43 is valuable for research applications focused on the modulation of inflammasome activity and its implications in various inflammatory diseases. -
NLRP3 Inhibitor
NLRP3-IN-41 is a selective inhibitor of the NLRP3 inflammasome, demonstrating significant anti-inflammatory and anti-neuroinflammatory effects without evident cytotoxicity. Its oral bioavailability and ability to penetrate the blood-brain barrier make it particularly valuable for studying the role of NLRP3 in neuroinflammatory conditions. NLRP3-IN-41 is suitable for research into inflammasome-related diseases, providing insights into the mechanism of NLRP3 activation and its contributions to pathological processes. -
NLRP3 Inhibitor
NLRP3-IN-37 is a potent inhibitor of the NLRP3 inflammasome, with an EC50 value of 5 nM. This compound is applicable in researching various NLRP3-related conditions, including gout, pseudogout, Cryopyrin-Associated Periodic Syndromes (CAPS), nonalcoholic steatohepatitis (NASH) fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's disease, Parkinson's disease, and traumatic brain injury. Its specificity for NLRP3 makes it a valuable tool in elucidating therapeutic approaches for these inflammatory disorders. -
NLRP3 Inflammasome Inhibitor
IIIM-1270 is a selective NLRP3 inflammasome inhibitor that effectively reduces the release of IL-1β in mouse macrophages (J774A.1 cells) with an IC50 of 3.5 μM. This compound significantly lowers the protein expression levels of mature IL-1β, making it a valuable tool for investigations into inflammatory pathways. IIIM-1270 is ideal for research applications focused on understanding the role of the NLRP3 inflammasome in various disease models related to inflammation. -
NLRP3 Inhibitor
NLRP3-IN-20 is a potent inhibitor of the NLRP3 inflammasome, exhibiting an IC50 value of 25 nM for the secretion of IL-1β. This compound possesses strong pharmacokinetic properties, making it suitable for in vivo studies. NLRP3-IN-20 has shown significant efficacy in various research models, including non-alcoholic steatohepatitis, fatal septic shock, and colitis, thereby serving as a valuable tool for investigating inflammation-related disorders. -
NLRP3 Inflammasome Inhibitor
Fc 11a-2 is a benzimidazole compound that functions as a potent inhibitor of the NLRP3 inflammasome. It effectively reduces the activation of caspase-1, leading to decreased secretion of pro-inflammatory cytokines IL-1b and IL-18. This compound has demonstrated protective effects in model systems, including the prevention of Dextran sulfate sodium-induced murine experimental colitis, making it valuable for research in inflammation and related diseases. -
NLRP3 Inhibitor
MS-II-124 is a potent and selective inhibitor of the NLRP3 inflammasome, demonstrating an IC50 of 0.12 μM. This compound exhibits significant anti-inflammatory and immunomodulatory activities, making it a valuable tool for research applications related to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Its targeted inhibition of NLRP3 positions MS-II-124 as a promising candidate for elucidating the roles of inflammasomes in various inflammatory diseases. -
NLRP3 Inhibitor
NLRP3-IN-67 is a potent inhibitor of the NLRP3 inflammasome, which plays a critical role in mediating inflammatory responses. This compound effectively attenuates NLRP3 activation, thereby reducing the production of pro-inflammatory cytokines. NLRP3-IN-67 is valuable for research applications focused on inflammation-related diseases, such as autoimmune disorders and chronic inflammatory conditions. -
NLRP3 Inhibitor
NLRP3-IN-63 is a potent inhibitor of the NLRP3 inflammasome, demonstrating an EC50 of 13 nM for NLRP3 activation inhibition. This compound provides a valuable tool for studying inflammatory responses and may aid in the research of diseases associated with NLRP3 dysregulation, such as autoinflammatory disorders and metabolic syndrome. Research applications include investigations into the mechanistic pathways of inflammation and the development of therapeutic strategies targeting NLRP3-related conditions. -
NLRP3 Inhibitor
NIC-12 is a selective NLRP3 inhibitor that effectively reduces circulating IL-1ß levels in models of LPS-induced endotoxemia in mice. This compound has been shown to inhibit NLRP3 inflammasome activation in mouse macrophages, making it a valuable tool for research into inflammatory responses and related diseases. Its application extends to studies focused on immunology and therapeutic interventions targeting NLRP3-related pathways. -
NLRP3 Inflammasome Inhibitor
IIIM-1266 is a potent NLRP3 inflammasome inhibitor that effectively inhibits the release of IL-1β in mouse macrophages (J774A.1 cells) with an IC50 of 2.3 μM. This compound significantly reduces the protein expression levels of mature IL-1β, making it a valuable tool for studying inflammation and its associated pathways in research settings. IIIM-1266 provides insights into the role of the NLRP3 inflammasome in inflammatory responses and potential therapeutic interventions. -
NLRP3 Inhibitor
NLRP3-IN-16 is a selective inhibitor of the NLRP3 inflammasome, demonstrating potent activity with an IC50 value of 0.065 μM for the inhibition of interleukin-1 beta (IL-1β) release. This compound provides valuable insights into the mechanisms of inflammation and is useful for research applications focused on inflammatory diseases and cellular stress responses. -
NLRP3 Inhibitor
NLRP3-IN-66 is a selective inhibitor of the NLRP3 inflammasome, which plays a crucial role in the activation of inflammatory responses. This compound demonstrates significant biological activity by reducing the production of pro-inflammatory cytokines, making it a valuable tool for research in inflammatory diseases. NLRP3-IN-66 is essential for studies targeting the modulation of the NLRP3 pathway in both in vitro and in vivo models. -
NLRP3 Modulator
NLRP3 Modulator 1 is a selective modulator targeting the NLRP3 inflammasome. This compound functions as an agonist or partial agonist, effectively enhancing NLRP3 activity. It is valuable for research into conditions, diseases, or disorders where reduced NLRP3 activity plays a role in disease pathology, facilitating studies on inflammation and immune responses. -
NLRP3 Inhibitor
NLRP3-IN-61 is a potent inhibitor of NLRP3, targeting the NLRP3 inflammasome pathway. This compound effectively inhibits pyroptosis in THP-1 cells with an IC50 value of 12.6 nM and reduces IL-1β release with an IC50 of 25.3 nM. NLRP3-IN-61 is suitable for research applications investigating inflammatory responses and therapeutic interventions in diseases associated with the NLRP3 inflammasome. -
NLRP3/URAT1 Inhibitor
NLRP3/URAT1-IN-1 is an orally active dual inhibitor targeting NLRP3 and URAT1, with an IC50 of 3.81 μM. This compound effectively inhibits IL-1β release in LPS- and ATP-stimulated mouse bone marrow-derived macrophages, demonstrating an IC50 of 2.61 μM. In vivo studies reveal that NLRP3/URAT1-IN-1 significantly reduces serum uric acid levels and mitigates liver and kidney damage in models of acute hyperuricemia. This reagent is essential for investigating the pathophysiology of gout and hyperuricemia. -
NOD-like Receptor (NLR) Inhibitor
Apilimod hydrochloride is an inhibitor of the PIKFYVE kinase, targeting the NOD-like receptor (NLR) pathway. This compound facilitates the activation of NLRP3 inflammatory vesicles and promotes the secretion of IL-1β. Its ability to inhibit host cell proteases may prevent viral invasion; however, it may also obstruct antiviral immune responses, which could lead to increased immunosuppression in conditions such as COVID-19. Research applications include studies on inflammation, immune response regulation, and viral pathogenesis. -
NLRP3 Degrader
MC-ND-18 is an ATTEC degrader targeting NLRP3, functioning primarily through autophagic pathways. With a DC50 value of 125.5 nM in THP-1 cells, this compound facilitates the selective degradation of NLRP3. Composed of a ligand specific to NLRP3, a linker, and an LC3 ligand, MC-ND-18 is valuable for research investigating inflammation and diseases associated with NLRP3 activation. -
NLRP3 Inflammasome Inhibitor
YM-I-26 is a selective inhibitor of the NLRP3 inflammasome, effectively modulating inflammatory responses. It enhances the phagocytosis of β-amyloid protein by mouse microglial BV2 cells while concurrently inhibiting the secretion of pro-inflammatory cytokines IL-1β and IL-10. This compound is useful for investigating the role of the NLRP3 inflammasome in various inflammatory conditions and its potential as a therapeutic target in immune modulation. -
NLRP3 Inhibitor
Isoandrographolide is a selective inhibitor of the NLRP3 inflammasome, known for its potential to modulate inflammatory responses. This compound exhibits significant hepatoprotective effects and promotes cell differentiation. Research applications include studying the role of NLRP3 in inflammatory diseases and exploring therapeutic strategies for conditions such as silicosis. -
Sodium Channel Inhibitor
Articaine is a selective inhibitor of voltage-gated sodium channels, including rNav1.4, hNav1.7, and rNav1.8, demonstrating an IC50 of 15.8 μM for open-state Na+ channels. It effectively blocks Na+ influx, leading to local anesthetic effects and interruption of nerve impulse conduction. Additionally, Articaine exhibits anti-inflammatory properties by inhibiting NF-κB activation and the NLRP3 inflammasome pathway. This compound is valuable for research in dental anesthesia and inflammatory-related conditions, such as acute kidney injury.
